A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists has become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries
Medications such as semaglutide, tirzepatide, and retatrutide are often discussed because they target hormone pathways associated with hunger, metabolism, and body weight regulation
Overall, these MS-identified interactions suggest that the effect of GLP-1R PKA signalling at ERMCS might extend well beyond the MICOS complex into a more comprehensive programme of ER, mitochondria and lipid metabolic pathway regulation
Avoid scented lotions or products on the area
People taking GLP-1 medications may experience a range of positive effects: Lower blood sugar levels, leading to improved diabetes control Promote weight loss, which can improve overall health and lower the risk of related medical problems Lower the risk of heart attacks, strokes, and kidney disease in people with diabetes or those at high cardiovascular risk Improve liver health in people with metabolic dysfunction-associated steatotic liver disease (MASLD) Help lower blood pressure and cholesterol, supporting overall heart health Reduce appetite and food cravings, making healthy eating patterns easier to maintain Less likely than some other diabetes medicines to cause low blood sugar or unwanted weight gain Can provide meaningful and lasting results for people who have struggled to lose weight with lifestyle changes alone Are there specific lifestyle changes that work best with these medications
